FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to treating cardiovascular disease. Liquid pharmaceutical composition of neuregulin (NRG) contains: (a) NRG polypeptide; (b) a pH buffer agent; (c) a stabilizer; (d) sodium chloride, wherein said composition has pH of 2–5.7, where the NRG polypeptide concentration is in the concentration range of 0.01–0.99 g/l, the pH-buffer agent concentration is in range of 0.1–500 mM, where the stabilizer is in concentration of 0.1–200 g/l, where sodium chloride is in the concentration range of 100–500 mM.
EFFECT: invention provides treating a patient suffering or at risk of developing heart failure.
9 cl, 18 tbl, 5 ex, 14 dwg
